NJXB(600682)2024-08-30 09:22Financial Performance - Revenue for the first half of 2024 was RMB 3,251,092,037.64, a slight increase of 0.40% compared to the same period last year[14] - Net profit attributable to shareholders of the company was RMB 165,216,088.95, a significant decrease of 48.65% year-on-year[14] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 177,725,968.69, down 41.86% compared to the same period last year[15] - Net cash flow from operating activities was RMB 277,805,739.78, a decrease of 32.93% year-on-year[15] - Basic earnings per share decreased by 50% to 0.12 yuan from 0.24 yuan in the same period last year[16] - Diluted earnings per share also decreased by 50% to 0.12 yuan from 0.24 yuan in the same period last year[16] - Weighted average return on equity decreased by 0.91 percentage points to 0.95% from 1.86% in the same period last year[16] - Non-recurring gains and losses included government subsidies of 1,297,666.67 yuan and gains from financial assets and liabilities of 9,136,567.12 yuan[16] - Total revenue for the first half of 2024 reached RMB 3,251,092,037.64, a slight increase from RMB 3,237,999,385.85 in the same period of 2023[140] - Net profit for the first half of 2024 was RMB 234,803,490.44, a decrease from RMB 400,334,851.63 in the same period of 2023[141] - Operating profit for the first half of 2024 was RMB 368,012,014.56, a decrease from RMB 531,982,577.40 in the same period of 2023[141] - Research and development expenses for the first half of 2024 were RMB 116,141,878.23, slightly down from RMB 119,714,256.18 in the same period of 2023[140] - Total operating costs for the first half of 2024 were RMB 2,869,991,133.84, up from RMB 2,725,070,370.50 in the same period of 2023[140] - Revenue for the first half of 2024 was RMB 264.23 million, compared to RMB 288.32 million in the same period of 2023[143] - Operating profit for the first half of 2024 was a loss of RMB 47.49 million, compared to a loss of RMB 13.53 million in the same period of 2023[145] - Net profit for the first half of 2024 was a loss of RMB 61.09 million, compared to a loss of RMB 11.22 million in the same period of 2023[145] - Basic earnings per share for the first half of 2024 were RMB -0.05, compared to RMB -0.01 in the same period of 2023[145] - Total comprehensive income for the first half of 2024 was RMB -61.02 million, compared to RMB -10.55 million in the same period of 2023[145] - Cash flow from operating activities for the first half of 2024 was RMB 277.81 million, compared to RMB 414.22 million in the same period of 2023[146] - Sales revenue from goods and services for the first half of 2024 was RMB 3.92 billion, compared to RMB 4.20 billion in the same period of 2023[146] - Cash paid for goods and services in the first half of 2024 was RMB 1.66 billion, compared to RMB 1.82 billion in the same period of 2023[146] - Cash paid to employees in the first half of 2024 was RMB 1.39 billion, compared to RMB 1.37 billion in the same period of 2023[146] - Cash paid for taxes in the first half of 2024 was RMB 207.94 million, compared to RMB 200.18 million in the same period of 2023[146] - Investment cash outflow totaled 1,031,745,814.57 yuan, a decrease of 20.4% compared to the previous period[147] - Net cash flow from investment activities was -689,417,972.49 yuan, a significant decline from -255,934,712.47 yuan in the previous period[147] - Net cash flow from financing activities was -25,039,146.40 yuan, compared to 31,593,838.43 yuan in the previous period[147] - Cash and cash equivalents at the end of the period were 4,512,798,517.10 yuan, a decrease of 12.0% from the previous period[147] - Operating cash inflow was 830,255,185.31 yuan, a decrease of 14.7% compared to the previous period[148] - Net cash flow from operating activities was -33,412,555.44 yuan, slightly worse than -31,933,786.37 yuan in the previous period[148] - Investment cash inflow was 32,402,250.00 yuan, a significant increase from 3,198,857.34 yuan in the previous period[149] - Net cash flow from investment activities was 22,353,170.31 yuan, a decrease of 44.8% compared to the previous period[149] - Net cash flow from financing activities was 37,916,946.54 yuan, a decrease of 19.6% compared to the previous period[149] - Cash and cash equivalents at the end of the period were 165,280,806.73 yuan, a decrease of 46.0% from the previous period[149] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 26,020,091,860.95, an increase of 1.17% compared to the end of the previous year[15] - The asset-liability ratio remained stable at 27.28%, showing no significant change[15] - Total assets as of the end of the first half of 2024 amounted to RMB 17,303,724,500.92, showing minimal change from RMB 17,293,824,254.85 at the end of the same period in 2023[138] - Total liabilities for the first half of 2024 were RMB 5,325,016,956.91, up from RMB 5,213,919,609.48 in the same period of 2023[139] - Long-term equity investments as of the end of the first half of 2024 stood at RMB 11,964,840,834.38, showing a slight decrease from RMB 11,978,165,636.71 at the end of the same period in 2023[138] - Total equity attributable to shareholders as of the end of the first half of 2024 was RMB 11,978,707,544.01, down from RMB 12,079,904,645.37 at the end of the same period in 2023[139] - Interest income for the first half of 2024 was RMB -80,742,669.62, compared to RMB -68,785,546.39 in the same period of 2023[141] - Total assets increased to 26,020,091,860.95 RMB, up from 25,719,533,432.05 RMB at the end of 2023[134][136] - Cash and cash equivalents decreased to 4,571,368,460.76 RMB from 5,000,758,404.36 RMB at the end of 2023[134] - Trade receivables increased to 1,444,731,695.63 RMB, up from 1,347,231,606.81 RMB at the end of 2023[134] - Inventory rose to 516,869,668.48 RMB, compared to 456,718,566.56 RMB at the end of 2023[134] - Total liabilities increased to 7,097,829,469.68 RMB, up from 7,017,213,664.98 RMB at the end of 2023[135][136] - Contract liabilities increased to 3,376,072,068.37 RMB, up from 3,298,076,377.01 RMB at the end of 2023[135] - Total equity increased to 18,922,262,391.27 RMB, up from 18,702,319,767.07 RMB at the end of 2023[136] - Development expenditure increased to 257,753,949.49 RMB, up from 229,987,339.85 RMB at the end of 2023[135] - Short-term borrowings increased to 551,458,997.22 RMB, up from 530,471,645.83 RMB at the end of 2023[135] - Other receivables in the parent company increased to 2,690,810,835.69 RMB, up from 2,550,304,841.54 RMB at the end of 2023[137] - Overseas assets amounted to 9.836 billion RMB, accounting for 37.80% of total assets[56] - Restricted assets totaled 1.35 billion RMB, including mortgage loans for properties such as the Xuzhou New Health Hospital outpatient building[58][59][60] - Long-term equity investments decreased by 13.32 million RMB to 425.91 million RMB due to equity method accounting for joint ventures[61] - Other equity instrument investments increased by 31 million RMB to 1.531 billion RMB, driven by new investments of 30 million RMB[61] - Securities investments totaled 510.03 million RMB, including stocks like Ninghu Expressway and Nanjing Securities[62] - The company invested 10,000 million RMB in Shanghai Xunchuang Investment Management Center, with 5,000 million RMB already transferred[63] - The company invested 40,000 million RMB in Nanjing Yingpeng Huikang Medical Industry Investment Partnership, with full payment completed[63] - The company's subsidiary invested 62,930 million RMB in Xinlu Dazeshengke (Hainan) Private Equity Fund Partnership, with 46,900 million RMB already paid[64] Subsidiaries and Business Operations - The company has subsidiaries such as Ankangtong, Hekang, and Dendreon, which are involved in healthcare and biotechnology sectors[6] - Ankang Tong has covered over 20 million elderly users and provided 200 million home care services[19] - Hekang serves over 12 million elderly users annually across more than 234 districts in over 10 provinces[21] - Natali successfully acquired UK home care service companies Nobilis and Horizon, expanding into the UK market[21] - A.S. Nursing provides home care services primarily to elderly individuals over 75 years old, disabled veterans, and other disabled persons, with services billed based on care hours by the Israeli National Insurance Institute[22] - Natali (China) focuses on two main business lines: family health management services and integrated health and elderly care services, aiming to become a data-driven, user-centric high-end health management service provider[23] - Shandong Qilu Stem Cell Engineering Co., Ltd. specializes in umbilical cord blood stem cell testing, preparation, storage, and provision, serving pregnant women and hospitals[24] - Dendreon US, a subsidiary of Shidai Hong Kong, focuses on the development, production, and sales of tumor cell immunotherapy products, with its flagship product PROVENGE approved by the FDA in 2010[25] - PROVENGE has been used in over 40,000 patients in the US, capturing 10% of the prostate cancer treatment market, and is currently undergoing Phase III clinical trials in China with 108 out of 140 planned patients enrolled[25] - Nanjing Dendreon's main asset, Dendreon China, is advancing the clinical development of PROVENGE in China, with positive efficacy and safety results observed in ongoing trials[25] - The company operates one of the 7 approved cord blood banks in China, located in Shandong province[27] - The hospital provides specialized medical services across 14 departments, including cardiology, neurology, and oncology[27] - The hospital conducts clinical education for Xuzhou Medical University and provides technical guidance to lower-tier medical institutions[27] - The company's health and elderly care business, Ankangtong, has developed a comprehensive elderly care service system with over 100 software copyrights and a standardized operational framework[34] - Ankangtong has established a big data ecosystem for elderly care, enabling service process supervision, dynamic quality analysis, and user assessment[34] - Hekang, another elderly care service provider, serves nearly 4 million elderly across 10 provinces and over 200 districts, offering a full range of care services[34] - Hekang has developed a smart elderly care big data system, enabling service capability sharing and development of smart nursing homes, medical services, and communities[34] - Natali, a global elderly care service provider, has a unique business model integrating remote medical and care services, with a strong focus on the 73-75+ age group[35] - Natali's business model is highly replicable, with 30+ years of operational experience enabling rapid international expansion[35] - Natali and A.S. Nursing have established vertical synergy, with Natali's emergency and remote medical services identifying potential users for A.S. Nursing's home care services[35] - Natali (China) has optimized its home care products to include the most efficient home monitoring modes, such as 24-hour dynamic ECG and blood pressure monitoring, significantly reducing hardware procurement and service operation costs[36] - Natali (China) leverages the synergy with Ankangtong, which provides target user data and a mature offline service team to support the implementation of high-end customized home care services[36] - Qilu Stem Cell has a large customer base with nearly 20 years of development, providing a rich cell resource foundation for diversified products and services[36] - Qilu Stem Cell has established a comprehensive service network, covering secondary and above hospitals in Shandong Province and collaborating with hospitals in over 20 provinces across China[37] - Qilu Stem Cell has a robust operational management system, including a real-time tracking mechanism for departmental plans and a two-way communication system to ensure strategic implementation[38] - Dendreon US has over 20 years of R&D experience in cell immunotherapy for mCRPC patients, with a mature production process and FDA-certified treatment protocols[39] - Dendreon China is actively expanding its industrial layout, planning to build a GMP-compliant commercial cell factory to meet future production needs for PROVENGE® and other cell products[40] - New Health Hospital has introduced high-quality medical resources and established a comprehensive cooperation model with Jiangsu Provincial People's Hospital, including expert workstations and specialized outpatient services[40] - Ankangtong successfully bid for 82 projects and expanded to 3 new cities: Yinchuan, Yuncheng, and Huzhou[43] - Ankangtong's smart product library includes approximately 100 smart products across 9 categories and 200 non-smart products across 8 categories[43] - Ankangtong won the "2024 Digital Intelligence Elderly Care Benchmark Enterprise" award[44] - Natali's cumulative revenue increased by 10.7% year-on-year, with nursing business and private payment business revenues growing by 9.6% and 13.6% respectively[45] - Natali added over 800 core private payment users and sold more than 1,400 smart wearable devices[45] - A.S. Nursing provided 5.5 million hours of nursing services, expanding its user base in Israel[45] - Natali (China) expanded its business scope with insurance companies, adding high-end elderly care services, aging-friendly renovations, and health tourism[45] - Natali successfully acquired UK home care service companies Nobilis and Horizon, establishing a UK operational platform[45] - Natali acquired a 30% minority stake in subsidiary SHARAP, focusing on medical and emergency services in rural Israel[45] - QiLu Stem Cell optimized its stem cell service system and passed the blood station license renewal inspection[47] - QiLu Stem Cell organized a stem cell clinical application and regenerative medicine conference, enhancing brand influence[47] - QiLu Stem Cell conducted research on umbilical cord blood mononuclear cell composition analysis and umbilical plasma exosome effectiveness, achieving phased results[47] - Dendreon USA strengthened the product positioning of PROVENGE as a therapy for early-stage asymptomatic or mildly symptomatic mCRPC patients[49] - DanRui USA completed the optimization of its sales organization structure, enhancing sales service capabilities[50] - DanRui USA deepened its collaboration with Shoreline in 2023, successfully delivering the first GMP production batch and advancing NK cell production services[51] - DanRui USA evaluated over 200 projects since 2022, focusing on those with high potential and synergy for further research[51] - DanRui China enrolled 108 patients in the PROVENGE Phase III clinical trial, out of a planned total of 140 patients, as of June 2024[51] - DanRui China implemented strategic planning to establish a sustainable business model, leveraging PROVENGE as a key product[52] - New Health Hospital recorded over 207,000 outpatient visits and approximately 26,000 inpatient discharges in the first half of 2024[52] - DanRui's revenue for the first half of 2024 was RMB 3.251 billion, a 0.4% increase year-over-year[53] - DanRui's management expenses increased by 20.01% to RMB 686.07 million in the first half of 2024[53] - DanRui's financial expenses decreased by 47.87% to RMB -47.64 million due to increased deposit interest income[53] - DanRui's investment activities resulted in a net cash outflow of RMB 689.42 million, primarily due to the purchase of financial products[53] - Sanpower International Healthcare Group Ltd reported revenue of 738.03 million RMB and net profit of 37.10 million RMB[57] - Shiding Shengwu Biotechnology (Hong Kong) Trading Limited reported revenue of 776.40 million RMB and net profit of 75.24 million RMB[57] - Xuzhou New Health Geriatric Hospital Co., Ltd. achieved a net profit of 364.197 million yuan, a 27.13% increase compared to the previous year[65] - Shandong Qilu Stem Cell Engineering Co., Ltd. reported a net profit of 3,173.251 million yuan, a 9.53% decrease compared to the previous year[65] - Sanpower International Healthcare Group Co., Ltd. recorded a net profit of 370.